Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study

Roberto Fogari, Annalisa Zoppi, Luigi Poletti, Gianluigi Marasi, Amedeo Mugellini, Luca Corradi

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

The aim of this study was to compare the effect of anti-hypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] ≥ 95 mm Hg and <110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48% of normalization with valsartan and 45% with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P <.01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5%), one patient with valsartan (0.9%), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalAmerican Journal of Hypertension
Volume14
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Valsartan
Sexual Behavior
Cross-Over Studies
Coitus
Placebos
Blood Pressure
carvedilol
Erectile Dysfunction
Therapeutics

Keywords

  • Carvedilol
  • Hypertension
  • Sexual activity
  • Valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sexual activity in hypertensive men treated with valsartan or carvedilol : A crossover study. / Fogari, Roberto; Zoppi, Annalisa; Poletti, Luigi; Marasi, Gianluigi; Mugellini, Amedeo; Corradi, Luca.

In: American Journal of Hypertension, Vol. 14, No. 1, 2001, p. 27-31.

Research output: Contribution to journalArticle

Fogari, Roberto ; Zoppi, Annalisa ; Poletti, Luigi ; Marasi, Gianluigi ; Mugellini, Amedeo ; Corradi, Luca. / Sexual activity in hypertensive men treated with valsartan or carvedilol : A crossover study. In: American Journal of Hypertension. 2001 ; Vol. 14, No. 1. pp. 27-31.
@article{0966bc65932f4ccebb85689c4f9b616d,
title = "Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study",
abstract = "The aim of this study was to compare the effect of anti-hypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] ≥ 95 mm Hg and <110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48{\%} of normalization with valsartan and 45{\%} with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P <.01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5{\%}), one patient with valsartan (0.9{\%}), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.",
keywords = "Carvedilol, Hypertension, Sexual activity, Valsartan",
author = "Roberto Fogari and Annalisa Zoppi and Luigi Poletti and Gianluigi Marasi and Amedeo Mugellini and Luca Corradi",
year = "2001",
doi = "10.1016/S0895-7061(00)01214-0",
language = "English",
volume = "14",
pages = "27--31",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Sexual activity in hypertensive men treated with valsartan or carvedilol

T2 - A crossover study

AU - Fogari, Roberto

AU - Zoppi, Annalisa

AU - Poletti, Luigi

AU - Marasi, Gianluigi

AU - Mugellini, Amedeo

AU - Corradi, Luca

PY - 2001

Y1 - 2001

N2 - The aim of this study was to compare the effect of anti-hypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] ≥ 95 mm Hg and <110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48% of normalization with valsartan and 45% with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P <.01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5%), one patient with valsartan (0.9%), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.

AB - The aim of this study was to compare the effect of anti-hypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] ≥ 95 mm Hg and <110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48% of normalization with valsartan and 45% with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P <.01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5%), one patient with valsartan (0.9%), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.

KW - Carvedilol

KW - Hypertension

KW - Sexual activity

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=0035142782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035142782&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(00)01214-0

DO - 10.1016/S0895-7061(00)01214-0

M3 - Article

C2 - 11206674

AN - SCOPUS:0035142782

VL - 14

SP - 27

EP - 31

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 1

ER -